ProGenis Pharmaceuticals

What ProGenis Pharmaceuticals does

ProGenis Pharmaceuticals is a clinical-stage, private biotechnology company headquartered in Bentley, Western Australia, with a US office in Boston, Massachusetts. Founded in 2022 by Prof. Marvin H. Caruthers and Prof. Rakesh N. Veedu, the company is developing next-generation precision RNA therapeutics, with a particular focus on antisense oligonucleotides (ASOs) that bind messenger RNA to modulate disease-causing protein production. Its end-user segments are patients with Type 2 Diabetes (primary, via lead candidate PGP-011 targeting insulin resistance) and patients with rare genetic diseases including Duchenne Muscular Dystrophy (secondary, via IP in-licensed from Murdoch University).

The company's core technical asset is a proprietary Thiomorpholino Oligonucleotide (TMO) chemistry platform, developed over six years of R&D across Murdoch University, the Perron Institute, and the University of Colorado Boulder. ProGenis claims TMO delivers superior exon skipping activity at very low doses relative to existing nucleic-acid chemistries and is compatible with standard solid-phase oligonucleotide synthesis. Supporting assets include a Scientific Advisory Board chaired by Dr. Sudhir Agrawal (founder of Idera Pharmaceuticals) and clinical advisors in metabolic and cardiovascular disease affiliated with the University of Western Australia and Fiona Stanley Hospital.

ProGenis is pre-revenue and funds operations through non-dilutive Australian grants, including the MRFF Targeted Translation Research Accelerator (via MTPConnect) and Future Health Research and Innovation funding. Its forward go-to-market is structured around advancing PGP-011 toward first-in-human trials and ultimately pursuing licensing/royalty monetization of its TMO platform and pipeline. Strategic positioning is supported by regional recognition (2025 Rio Tinto Emerging Innovation Award, WA Innovators of the Year) and academic partnerships, but the company has no commercial products, no disclosed institutional equity investors, and limited disclosed capital to date.

Name

ProGenis Pharmaceuticals

Legal name

ProGenis Pharmaceuticals

Website

https://progenispharma.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

ProGenis Pharmaceuticals is a clinical-stage, pre-revenue Australian biotech developing precision RNA therapeutics via its proprietary Thiomorpholino (TMO) antisense oligonucleotide platform, with lead candidate PGP-011 targeting insulin resistance in Type 2 Diabetes and a secondary rare-disease pipeline including Duchenne Muscular Dystrophy.

Ownership category

akta.pro rank

Product category

RNA Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• RNA therapeutics
• Antisense oligonucleotide therapeutics
• Precision biotechnology medicines
• Clinical-stage biotechnology
• Rare disease therapeutics

Headquarters

HQ city

Bentley

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. RNA Therapeutic Development: As a pre-revenue biotech company, ProGenis is focused on developing RNA-based therapeutics (lead candidate PGP-011 for Type 2 Diabetes) through clinical development toward commercialization. The company is pursuing MRFF TTRA funding and grant programs to finance R&D operations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ProGenis Pharmaceuticals is a clinical-stage biotechnology company that develops precision RNA therapeutics based on its proprietary Thiomorpholino Oligonucleotide (TMO) chemistry platform. It engineers antisense oligonucleotide (ASO) drugs that bind messenger RNA to regulate disease-causing proteins, with lead candidate PGP-011 targeting insulin resistance in Type 2 Diabetes and additional programs addressing Duchenne Muscular Dystrophy and other muscular diseases.

Product overview

ProGenis Pharmaceuticals is a single-product biotechnology company focused on developing next-generation RNA therapeutics using its proprietary Thiomorpholino Chemistry Platform (TMO). The core product portfolio centers on PGP-011, a lead RNA therapeutic candidate for type 2 diabetes that has received MRFF TTRA funding, with PGP-011D representing a consumer-facing variant of the same therapeutic program. The company develops antisense oligonucleotides (ASOs) that bind to mRNA to regulate disease-causing protein production, targeting both chronic metabolic diseases and rare genetic disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• PGP-011 Lead RNA therapeutic candidate designed to improve insulin sensitivity and overall health outcomes for people living with Type 2 Diabetes. Demonstrated superior efficacy in reducing expression of the insulin-resistance causing gene in cellular and mouse T2D models, with reduced blood glucose levels and reduced insulin resistance observed. Targeted at patients with Type 2 Diabetes rather than as a symptom-management glucose-lowering therapy.
• Duchenne Muscular Dystrophy (DMD) Therapeutic Program Antisense oligonucleotide program for Duchenne Muscular Dystrophy and multiple other muscular diseases, built on patented technology licensed-in from Murdoch University via Patent Assignment Agreement and developed using the proprietary TMO chemistry platform.
• Thiomorpholino Oligonucleotide (TMO) Chemistry Platform Proprietary antisense oligonucleotide chemistry platform underpinning all ProGenis RNA therapeutic candidates. TMO is a newly developed robust class of therapeutic RNA chemistry efficiently synthesised using solid-phase oligonucleotide synthesis methodologies, exhibiting exon skipping activity at extremely low doses and superior splice switching compared to other nucleic acid chemistries.

Quantifiable outcome

• PGP-011 demonstrated superior efficacy in reducing expression of insulin-resistance causing gene in cellular and mouse models of T2D
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and supporting.

• Murdoch UniversitycoreStrategic or Co-development Partner · 3 July 2023Patent Assignment Agreement with Murdoch University, Western Australia, to develop novel treatment for Duchenne Muscular Dystrophy and multiple other muscular diseases. Agreement enables ProGenis to leverage patented technology developed by Murdoch University's top researchers, accelerating development of cutting-edge therapeutic solutions.
• Diabetes WAsupportingStrategic or Co-development PartnerProGenis is working closely with Diabetes WA, a community and consumer organisation, to advance PGP-011 toward clinical translation. Diabetes WA supports consumer engagement and outreach for the diabetes program.
• Perron InstitutesupportingStrategic or Co-development PartnerResearch partner contributing to the six years of pioneering R&D that formed the foundation of ProGenis Pharmaceuticals. Perron Institute contributes expertise in neurological and neurological rehabilitation research.
• Oligonucleotide Therapeutics Society (OTS)supportingGTM or Marketing PartnerProGenis is a sponsor of the First Nucleic Acid Therapeutics Regional Meeting - India 2025, supported by a Regional Delivery Grant from OTS. Managing Director Dr. Rakesh N. Veedu serves as a key speaker at the event.
• MTPConnect / TTRA CohortsupportingStrategic or Co-development PartnerProGenis participated in the official launch of the TTRA Drugs & Devices Program in Melbourne as part of the cohort of 14 companies, working in collaboration with MTPConnect and impact partners CSL and Roche Diagnostics Australia.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Ionis Pharmaceuticals: Pioneer and largest antisense oligonucleotide (ASO) therapeutics company. Direct peer given ProGenis's ASO-based TMO platform and similar targeting of genetic and metabolic diseases; serves as the primary benchmark for ASO pipeline economics.
• Sarepta Therapeutics: Leader in RNA-based therapeutics for Duchenne muscular dystrophy (eteplirsen, golodirsen, casimersen). Direct peer for ProGenis's DMD program via the Murdoch University patent assignment.
• Wave Life Sciences: Clinical-stage RNA therapeutics company with a proprietary stereopure oligonucleotide chemistry platform. Most directly comparable peer to ProGenis's TMO chemistry-platform strategy.
• ProQR Therapeutics: Clinical-stage RNA editing / antisense oligonucleotide company focused on rare genetic diseases. Comparable in stage, modality (ASO-based), and target disease areas.
• Stoke Therapeutics: Clinical-stage ASO company using antisense-mediated exon inclusion (TANGO platform) to upregulate protein expression in genetic diseases. Highly comparable modality and indication focus.
• Dyne Therapeutics: Clinical-stage company developing oligonucleotide therapeutics for muscle diseases including Duchenne muscular dystrophy and DM1. Direct comparator in the DMD indication.

Broad incumbents

• Alnylam Pharmaceuticals: Established leader in RNA-based therapeutics (siRNA platform, Onpattro, Givlaari, Oxlumo). Broader incumbent in RNA medicines with overlapping modality but distinct mechanism and indication portfolio.
• BioMarin Pharmaceutical: Established rare-disease focused biotech with multiple approved therapies. Broader incumbent in the rare/genetic disease commercial space relevant to ProGenis's DMD aspirations.

Emerging players

• Edgewise Therapeutics: Clinical-stage company developing therapeutics for muscle disorders including Duchenne muscular dystrophy. Emerging player in the same indication space as ProGenis's DMD program.
• Capricor Therapeutics: Late-stage biotech developing cell therapy and exosome-based treatments for Duchenne muscular dystrophy. Comparable emerging DMD-focused peer with overlapping clinical-stage positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/progenis-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProGenis Pharmaceuticals